Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ELMD 
Electromed Inc (ELMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: ELMD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 35.63% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.65M USD | Price to earnings Ratio 32.2 | 1Y Target Price 37 |
Price to earnings Ratio 32.2 | 1Y Target Price 37 | ||
Volume (30-day avg) 105671 | Beta 0.41 | 52 Weeks Range 13.74 - 35.56 | Updated Date 04/2/2025 |
52 Weeks Range 13.74 - 35.56 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.34% | Operating Margin (TTM) 15.64% |
Management Effectiveness
Return on Assets (TTM) 10.9% | Return on Equity (TTM) 16.11% |
Valuation
Trailing PE 32.2 | Forward PE - | Enterprise Value 190755056 | Price to Sales(TTM) 3.47 |
Enterprise Value 190755056 | Price to Sales(TTM) 3.47 | ||
Enterprise Value to Revenue 3.2 | Enterprise Value to EBITDA 19.94 | Shares Outstanding 8556840 | Shares Floating 6816211 |
Shares Outstanding 8556840 | Shares Floating 6816211 | ||
Percent Insiders 20.54 | Percent Institutions 43.56 |
Analyst Ratings
Rating 5 | Target Price 33 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Electromed Inc
Company Overview
History and Background
Electromed, Inc. (ELMD) was founded in 1980. It is a medical device company focused on developing, manufacturing, and marketing airway clearance technologies that help people breathe easier. The company's SmartVest Airway Clearance System is designed to loosen, thin, and move retained secretions to the upper airways where they can be coughed or suctioned away, helping to reduce the risk of respiratory infections and hospitalizations.
Core Business Areas
- Airway Clearance Systems: Electromed's primary business segment revolves around the SmartVest Airway Clearance System, which uses High Frequency Chest Wall Oscillation (HFCWO) therapy. They also sell related accessories and disposables.
- Service and Support: Electromed provides ongoing service, support, and training related to its products. This includes working with healthcare professionals and patients.
Leadership and Structure
Kathleen S. Skarvan is the President and Chief Executive Officer. The organizational structure consists of various departments including sales, marketing, research and development, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- SmartVest Airway Clearance System: The SmartVest system is the core product, a HFCWO device used to mobilize secretions in patients with compromised airway clearance. Market share data is estimated to be between 20% and 30% within the HFCWO market. Competitors include Hillrom (Baxter), RespirTech (Philips).
Market Dynamics
Industry Overview
The airway clearance market is driven by the increasing prevalence of chronic respiratory diseases such as cystic fibrosis, bronchiectasis, and COPD. Technological advancements and increasing adoption of home-based healthcare are also contributing to market growth.
Positioning
Electromed is positioned as a provider of HFCWO therapy, focusing on patient comfort and ease of use with the SmartVest system. Competitive advantages include a strong sales team and focus on patient education.
Total Addressable Market (TAM)
The TAM for airway clearance devices is estimated at USD $500 million annually. Electromed's positioning allows it to capture a portion of the HFCWO segment of this market.
Upturn SWOT Analysis
Strengths
- Strong brand reputation within the HFCWO market
- Focus on patient comfort and ease of use
- Dedicated sales force and patient education programs
- Established reimbursement pathways for SmartVest
Weaknesses
- Limited product diversification beyond HFCWO therapy
- Reliance on Medicare and other insurance reimbursement
- Smaller scale compared to larger competitors
- Potential vulnerability to changing reimbursement policies
Opportunities
- Expansion into new geographic markets
- Development of new airway clearance technologies
- Partnerships with healthcare providers and advocacy groups
- Increasing awareness of the benefits of HFCWO therapy
Threats
- Competition from larger medical device companies
- Changes in healthcare reimbursement policies
- Technological advancements leading to alternative therapies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- HALO
- PRGO
Competitive Landscape
Electromed competes primarily on the basis of product features, ease of use, and sales force effectiveness. They must differentiate themselves from larger competitors with broader product portfolios.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Electromed has experienced moderate growth driven by increased adoption of HFCWO therapy and expansion of its sales force.
Future Projections: Analysts project continued growth based on increasing awareness of the benefits of HFCWO therapy and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding the sales force, enhancing patient education programs, and developing new marketing strategies.
Summary
Electromed is a niche player in the airway clearance market, with a solid presence in HFCWO therapy. Its strengths lie in its SmartVest system, patient focus, and reimbursement pathways. However, it needs to diversify its product line and navigate the changing reimbursement landscape. The company will continue to grow steadily as the market demands higher end products
Similar Companies
HALO
Halozyme Therapeutics Inc
HALO
Halozyme Therapeutics Inc
PRGO
Perrigo Company PLC
PRGO
Perrigo Company PLC
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Electromed Inc
Exchange NYSE MKT | Headquaters New Prague, MN, United States | ||
IPO Launch date 2010-08-13 | President, CEO & Director Mr. James L. Cunniff | ||
Sector Healthcare | Industry Medical Devices | Full time employees 174 | Website https://smartvest.com |
Full time employees 174 | Website https://smartvest.com | ||
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.